Description

• General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
• Application: Tetracycline hydrochloride BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia. Also used in monographs such as:Lymecycline CapsulesChlortetracycline Eye OintmentChlortetracycline Veterinary Oral PowderChlortetracycline TabletsChlortetracycline OintmentDoxycycline TabletsDoxycycline Prolonged-Release CapsulesDoxycycline Dispersible TabletsDoxycycline CapsulesTetracycline TabletsTetracycline Capsules
• Biochem/physiol Actions: Mode of Action: Tetracycline passively diffuses through proin channels in the cell membrane, binding to 30S ribosomes and inhibits protein synthesis by preventing access of aminoacyl tRNA to the acceptor site on the mRNA-ribosome complex. It also binds to the bacterial 50S ribosomal subunit, altering the membrane and causing intracellular components to leak from bacterial cells. The inhibitory effects can be reversed by washing, suggesting that it is the reversibly bound antibiotic, and not the irreversibly bound drug, that is responsible for antibacterial action.Mode of Resistance: The effects are inactivated via a loss of cell wall permeability.Antimicrobial spectrum: Includes a wide range of antimicrobial activity against gram-positive and gram-negative bacteria.
• Packaging: Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia
• Other Notes: Sales restrictions may apply.